These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9221813)

  • 1. Vascularity and prognosis of metastatic melanoma.
    Vlaykova T; Muhonen T; Hahka-Kemppinen M; Pyrhönen S; Jekunen A
    Int J Cancer; 1997 Jun; 74(3):326-9. PubMed ID: 9221813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression.
    Vlaykova T; Laurila P; Muhonen T; Hahka-Kemppinen M; Jekunen A; Alitalo K; Pyrhönen S
    Melanoma Res; 1999 Feb; 9(1):59-68. PubMed ID: 10338335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma.
    Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Franssila K; Collan Y; Pyrhönen S
    Oncology; 1999 Oct; 57(3):242-52. PubMed ID: 10545794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of tumour vascularity in primary melanoma.
    Ilmonen S; Kariniemi AL; Vlaykova T; Muhonen T; Pyrhönen S; Asko-Seljavaara S
    Melanoma Res; 1999 Jun; 9(3):273-8. PubMed ID: 10465583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor vascularity as a prognostic indicator in intermediate-thickness (0.76-4 mm) cutaneous melanoma. A quantitative assay.
    Rongioletti F; Miracco C; Gambini C; Pastorino A; Tosi P; Rebora A
    Am J Dermatopathol; 1996 Oct; 18(5):474-7. PubMed ID: 8902093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma.
    Kashani-Sabet M; Sagebiel RW; Ferreira CM; Nosrati M; Miller JR
    J Clin Oncol; 2002 Apr; 20(7):1826-31. PubMed ID: 11919240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin.
    Busam KJ; Berwick M; Blessing K; Fandrey K; Kang S; Karaoli T; Fine J; Cochran AJ; White WL; Rivers J
    Am J Pathol; 1995 Oct; 147(4):1049-56. PubMed ID: 7573350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax.
    Tafra L; Dale PS; Wanek LA; Ramming KP; Morton DL
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):119-28; discussion 129. PubMed ID: 7609535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
    Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
    Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma.
    Pastushenko I; Van den Eynden GG; Vicente-Arregui S; Prieto-Torres L; Alvarez-Alegret R; Querol I; Dirix LY; Carapeto FJ; Vermeulen PB; Van Laere SJ
    Am J Dermatopathol; 2016 May; 38(5):338-46. PubMed ID: 26909582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.
    Nikkola J; Vihinen P; Vlaykova T; Hahka-Kemppinen M; Kähäri VM; Pyrhönen S
    Int J Cancer; 2002 Feb; 97(4):432-8. PubMed ID: 11802203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
    Bedikian AY; Legha SS; Mavligit G; Carrasco CH; Khorana S; Plager C; Papadopoulos N; Benjamin RS
    Cancer; 1995 Nov; 76(9):1665-70. PubMed ID: 8635073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
    Morton DL; Hsueh EC; Essner R; Foshag LJ; O'Day SJ; Bilchik A; Gupta RK; Hoon DS; Ravindranath M; Nizze JA; Gammon G; Wanek LA; Wang HJ; Elashoff RM
    Ann Surg; 2002 Oct; 236(4):438-48; discussion 448-9. PubMed ID: 12368672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uveal melanoma cell staining for CD34 and assessment of tumor vascularity.
    Chen X; Maniotis AJ; Majumdar D; Pe'er J; Folberg R
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2533-9. PubMed ID: 12147581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
    Kuk D; Shoushtari AN; Barker CA; Panageas KS; Munhoz RR; Momtaz P; Ariyan CE; Brady MS; Coit DG; Bogatch K; Callahan MK; Wolchok JD; Carvajal RD; Postow MA
    Oncologist; 2016 Jul; 21(7):848-54. PubMed ID: 27286787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
    Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
    Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.
    Manola J; Atkins M; Ibrahim J; Kirkwood J
    J Clin Oncol; 2000 Nov; 18(22):3782-93. PubMed ID: 11078491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.
    Moreira A; Leisgang W; Schuler G; Heinzerling L
    Immunotherapy; 2017 Jan; 9(2):115-121. PubMed ID: 28128709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gamma Knife radiosurgery for intracranial metastatic melanoma: an analysis of survival and prognostic factors.
    Koc M; McGregor J; Grecula J; Bauer CJ; Gupta N; Gahbauer RA
    J Neurooncol; 2005 Feb; 71(3):307-13. PubMed ID: 15735922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.